Nyxoah S.A. (NYXH): history, ownership, mission, how it works & makes money

A Brief History of Nyxoah S.A. (NYXH)

Foundation and Early Development

Nyxoah S.A. was founded in 2014, with headquarters located in Mont-Saint-Guibert, Belgium. The company focuses on developing innovative solutions for obstructive sleep apnea (OSA). The company’s flagship product, the Genio system, is designed for patients who are not effectively treated by continuous positive airway pressure (CPAP).

Product Development and Clinical Trials

Nyxoah’s Genio system received CE Mark approval in 2018, allowing it to be marketed in Europe. The system employs a unique approach by using neurostimulation to treat OSA. In June 2020, the company completed a pivotal clinical trial, known as the ADHERE study, demonstrating positive results with 85% of patients reporting improvement in their condition.

Financial Milestones

In 2020, Nyxoah reported a revenue of approximately €1.4 million, a significant increase from €0.6 million in 2019. The growth was attributable to the initial market launch of the Genio system in Europe.

IPO and Market Expansion

In 2021, Nyxoah went public on Euronext Brussels under the ticker symbol NYXH. The IPO raised approximately €25 million, with shares priced at €13 each. The funds were allocated for expanding its commercial footprint and furthering research and development activities.

Recent Developments

As of Q3 2023, Nyxoah announced an increase in its sales figures, reporting revenues of €3.2 million, which represents a 129% increase year-over-year. The company also received FDA approval for the Genio system in the United States in September 2023, paving the way for entry into the U.S. market.

Financial Overview

Collaborations and Partnerships

In 2022, Nyxoah entered into a partnership with a major U.S. healthcare provider to increase awareness and treatment options for OSA patients. The collaboration is expected to enhance the rollout of the Genio system across various healthcare settings.

Future Outlook

Nyxoah aims to leverage its recent U.S. FDA approval to expand its market presence and increase sales. The company has set a target revenue of €10 million by the end of 2024, with expectations of positive cash flow by 2025.

A Who Owns Nyxoah S.A. (NYXH)

Corporate Ownership Structure

Nyxoah S.A. operates under a defined corporate ownership structure. As of the latest reports in 2023, the company has a diverse set of institutional and individual shareholders.

Major Shareholders

Several key stakeholders significantly influence Nyxoah's strategic direction:

Recent Stock Performance

As of October 2023, Nyxoah S.A. trades on the Euronext Brussels with the following financial metrics:

• Current Share Price: €16.25
• Market Capitalization: €212.5 million
• 52-Week Range: €10.50 - €18.00
• Dividend Yield: 0% (no dividends paid)

Financial Overview

Financial performance metrics are essential to understanding the health of Nyxoah S.A.:

Future Outlook and Strategic Directions

Nyxoah is focused on expanding its market presence and aims to launch new products in the sleep apnea treatment space. This expansion is critical to maintaining the interest of both institutional and retail investors.

• Projected Revenue Growth: 30% CAGR over the next five years
• Upcoming Product Launch: Genio™ system expected in Q4 2023
• Partnerships: Collaborations with major healthcare providers announced

Nyxoah S.A. (NYXH) Mission Statement

Corporate Vision

Nyxoah S.A. aims to redefine sleep apnea treatment through innovative solutions that prioritize patient comfort and improve health outcomes. The company is dedicated to transforming the landscape of sleep-disordered breathing, ensuring its products deliver not only functionality but enhanced quality of life for patients.

Key Objectives

• Develop cutting-edge medical devices for the treatment of obstructive sleep apnea (OSA).
• Enhance patient accessibility to life-changing therapies.
• Foster strong partnerships with healthcare providers and stakeholders.
• Expand global market presence while maintaining compliance with regulatory standards.

Target Market

Nyxoah focuses on a global population suffering from OSA, estimated at 936 million individuals worldwide according to the latest research from the American Academy of Sleep Medicine. The company specifically targets patients who find traditional CPAP therapy cumbersome or ineffective, providing alternative solutions.

Financial Performance

As of Q2 2023, Nyxoah reported a revenue of €3.8 million, showing growth compared to €2.5 million in the previous year. The company’s operating loss was reported at €12 million, reflecting ongoing investments in R&D and market expansion.

Product Offerings

Nyxoah’s flagship product is the Genio® system, a breakthrough solution for OSA treatment. This innovative device utilizes Hypoglossal Nerve Stimulation (HNS) technology:

Research and Development

Nyxoah allocates approximately 40% of its total expenditures to R&D. For 2023, R&D expenses are projected to reach €10 million.

Strategic Partnerships

• Collaboration with healthcare institutions for clinical studies.
• Partnership with leading sleep specialists for product validation.
• Engagement with reimbursement agencies to facilitate patient access.

Market Position

Nyxoah has established a strong position in the sleep apnea market, with a market share of approximately 7% in Europe as of 2023. The company continues to expand its footprint in North America and Asia-Pacific regions.

Commitment to Sustainability

Nyxoah is committed to sustainable practices, aiming to reduce carbon footprints in manufacturing processes by 20% by 2025. Initiatives also include responsible sourcing of materials used in devices.

Future Outlook

Looking ahead, Nyxoah anticipates entering new markets and launching additional products that align with its mission of enhancing oxygen delivery in patients with OSA. The company targets a revenue of €10 million by the end of 2024.

How Nyxoah S.A. (NYXH) Works

Company Overview

Nyxoah S.A. is a medical technology company focused on the development of innovative solutions for the treatment of obstructive sleep apnea (OSA). As of October 2023, Nyxoah's primary product is the Genio device, which is an innovative neurostimulation therapy designed to provide patients with relief from OSA.

Market Position and Financials

As of Q3 2023, Nyxoah has reported a market capitalization of approximately €200 million. The company’s stock is publicly traded on the Euronext Brussels under the ticker symbol NYXH.

In the financial year ending December 31, 2022, Nyxoah reported total revenues of €5.2 million, reflecting a significant increase from €2.1 million in 2021.

Product Development

The Genio device employs a unique approach to treating OSA through a minimally invasive procedure. The device is implanted with the assistance of a trained specialist, targeting the hypoglossal nerve to stimulate muscle activity in the airway.

Clinical Trials

Nyxoah has conducted multiple clinical trials to assess the efficacy and safety of the Genio device. Recent results from the trials demonstrated a success rate of approximately 76% in patients achieving a reduction in apnea-hypopnea index (AHI) by 50% or more.

Regulatory Approvals

As of Q3 2023, the Genio device has received regulatory approval in several key markets, including:

• European CE Mark
• FDA approval in the United States
• TGA approval in Australia

Sales Strategy

Nyxoah employs a direct sales model in Europe, coupled with a distributor-based approach in international markets, aiming to penetrate the global sleep apnea treatment market estimated to exceed €50 billion by 2025.

Partnerships and Collaborations

Nyxoah has established various partnerships, including:

• Collaboration with leading sleep centers across Europe
• Partnership with medical device distributors in Asia-Pacific regions
• Joint research initiatives with universities focused on sleep medicine

Future Outlook

Nyxoah is focused on expanding its market presence and is projected to increase its revenue by 40% annually through 2025, leveraging new product launches and geographic expansion efforts.

How Nyxoah S.A. (NYXH) Makes Money

Revenue Streams

Nyxoah S.A. operates primarily in the medical technology sector, focusing on providing innovative solutions for the treatment of obstructive sleep apnea (OSA). The company's primary revenue streams include:

• Sales of medical devices for OSA treatment
• Recurring revenue from service agreements
• Collaborations and partnerships with healthcare providers
• Clinical research and trials funded by third parties

Product Overview

Nyxoah's flagship product is the Genio system, a neurostimulation device aimed at patients who are unable to use CPAP therapy. The following table provides an overview of the revenue generated from product sales:

Service Agreements

In addition to device sales, Nyxoah has established various service agreements with healthcare institutions, which contribute to its recurring revenue model. The following table outlines the expected growth in service agreement revenue:

Clinical Trials and Research

Nyxoah also generates revenue through collaborations with various research organizations for clinical trials. The following are some key statistics related to their clinical research funding:

• Total funding received for trials in 2022: €1,200,000
• Number of active trials in 2023: 5
• Average duration of trials: 18 months
• Percentage of funding expected from government grants: 40%

Partnerships and Collaborations

Nyxoah has established significant collaborations with leading healthcare providers, enhancing its market reach. Here are details regarding their partnership revenue:

Market Position and Competitive Landscape

Nyxoah competes against other established brands in the OSA market. The following table presents a comparison of market capitalization and annual revenues of major competitors: